title: Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
abstract: BACKGROUND
  In an earlier study, intravenous (i.v.) ibandronate 6 mg administered every 3-4 weeks had a similarly good renal safety profile whether infused over 15 or 60 min in women with breast cancer and bone metastases. This current study focuses on the renal safety of the extended use of ibandronate.
  
  
  METHODS
  Patients completing the original study could choose to enter a follow-up phase and continue (or switch) to receive ibandronate 6 mg by 15-min i.v. infusion every 3-4 weeks. The primary endpoint was the percentage of patients with a serum creatinine increase of ≥44.2 mmol/l (= 0.5 mg/dl) from core baseline.
  
  
  RESULTS
  Fourteen patients entered the follow-up phase and received a median of 16 infusions (range: 9-24). No patient reached the primary endpoint. Most adverse events were mild to moderate in intensity. None of the 6 reported treatment-related adverse events was considered severe or reported as a serious adverse event.
  
  
  CONCLUSIONS
  Ibandronate was well tolerated when administered as a 6-mg i.v. infusion over 15 min every 3-4 weeks during the follow-up phase to the earlier core study. No evidence of any treatment-related deterioration in renal function was noted, and no new or unexpected adverse events occurred.
authors.affiliation: Medizinische Klinik, Onkologie und Hämatologie, Chur, Switzerland. roger.vonmoos@ksgr.ch
authors.forename: Roger
authors.initials: R
authors.lastname: von Moos
authors.forename: Clemens B
authors.initials: CB
authors.lastname: Caspar
authors.forename: Rolf
authors.initials: R
authors.lastname: Steiner
authors.forename: Rahel
authors.initials: R
authors.lastname: Angst
authors.forename: Roman
authors.initials: R
authors.lastname: Inauen
authors.forename: Kerstin
authors.initials: K
authors.lastname: Schmieding
authors.forename: Beat
authors.initials: B
authors.lastname: Thürlimann
mesh_terms: D000328:Adult; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis; D008137:Longitudinal Studies; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid